The earnings report itself is unlikely to move the stock materially. Focus shifts entirely to the imminent LOTIS-5 topline data, which is the key binary catalyst. Traders should watch for press release timing and prepare for volatility based on trial outcomes.
Price Chart
Executive Summary
ADC Therapeutics reported Q1 2026 product revenue of $20.0M (+15% YoY), in line with consensus, but GAAP net loss per share of ($0.21) slightly missed the ($0.20) consensus. The company reiterated its expected cash runway into 2028 and highlighted pending LOTIS-5 topline data in Q2 2026 as the primary near-term catalyst.
Key Financial Metrics
Key Facts
- Q1 2026 net product revenue: $20.0M, up from $17.4M in Q1 2025
- GAAP net loss $(0.21) per share vs consensus $(0.20) (small miss)
- Adjusted net loss $(0.13) per share improved from $(0.22) a year ago
- Cash and cash equivalents: $231.0M as of March 31, 2026
- LOTIS-5 Phase 3 topline data expected in Q2 2026 (any day)
- No financial guidance provided
Financial Impact
Q1 revenue in line, EPS miss of ~5% but adjusted loss improved; limited financial impact given pre-profit stage.
Risk Factors
- LOTIS-5 trial failure would significantly impair the stock
- Dilution risk from potential future financing needs
- Competitive pressure from other DLBCL therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-029524 |
| Document: adc-20260504.htm | 0001628280-26-029524 |
| Document: 0001628280-26-029524-index-headers.html | 0001628280-26-029524 |
| Document: 0001628280-26-029524-index.html | 0001628280-26-029524 |
| Document: 0001628280-26-029524.txt | 0001628280-26-029524 |
| 8-K Data (Synthetic) | 0001628280-26-029524 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 8-K | $1.70 $1.52 | ▼ −10.59% | ▼ −9.44% | $1.50 (−11.76%) |
Aug 6, 2026 11w ago | Press Release | $1.13 $1.05 | ▼ −7.08% | ▼ −8.29% | $1.50 (+32.74%) |
Jul 2, 2026 16w ago | 8-K | $1.19 $1.30 | ▲ +9.24% | ▲ +8.31% | $1.50 (+26.05%) |
Jun 3, 2026 20w ago | 8-K | $1.32 $1.06 | ▼ −19.70% | ▼ −17.14% | $1.50 (+13.64%) |
May 4, 2026 25w ago | 8-K | $3.68 $3.48 | ▼ −5.43% | ▼ −8.37% | $1.50 (−59.24%) |
Apr 20, 2026 27w ago | DEFA14A | $4.25 $3.76 | ▼ −11.53% | ▼ −12.44% | $1.50 (−64.71%) |
Mar 17, 2026 31w ago | EFFECT | $4.11 $3.94 | ▼ −4.14% | ▼ −1.48% | $1.50 (−63.50%) |
Mar 10, 2026 32w ago | S-3 | $4.88 $4.01 | ▲ +17.83% | ▲ +15.64% | $1.50 (+69.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers